NIPPON BOEHRINGER INGELHEMI TO SOLELY MARKET ALESION ANTI-ALLERGIC AGENT

Nippon Boehringer Ingelheim announced on July 28 that it has agreed with Sankyo on sales of Alesion. Specifically, Nippon Boehringer Ingelheim will solely market the agent beginning on September 28. Developed by Nippon Boehringer Ingelheim, Alesion is a once-daily, non-sedative anti-allergic agent prescribed for the treatment of bronchial asthma (adult patients only), allergic rhinitis, and allergic dermatitis.

Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=10589)